MannKind traded at $4.05 this Tuesday July 5th, increasing $0.07 or 1.76 percent since the previous trading session. Looking back, over the last four weeks, MannKind gained 6.68 percent. Over the last 12 months, its price fell by 22.41 percent. Looking ahead, we forecast MannKind to be priced at 3.87 by the end of this quarter and at 3.57 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Adma Biologics 2.13 0.10 4.93% 41.06%
BioCryst Pharmaceuticals 11.14 0.30 2.77% -31.36%
ChemoCentryx 26.85 0.09 0.34% 91.10%
Dynavax Technologies 14.02 1.06 8.18% 47.58%
Halozyme Therapeutics 46.64 0.31 0.66% 0.96%
Immunogen 4.90 0.29 6.29% -21.60%
Insmed 21.28 0.39 1.87% -24.16%
Jazz Pharmaceuticals 160.04 1.46 0.92% -12.51%
Karyopharm Therapeutics 5.31 0.58 12.26% -47.48%
Eli Lilly 328.64 1.46 0.45% 39.60%
MacroGenics 3.31 0.26 8.52% -88.38%
MannKind 4.05 0.07 1.76% -22.41%
Merck & Co 94.17 1.53 1.65% 20.56%
Minerva Neurosciences 3.25 -0.34 -9.47% 40.09%
Novavax 64.29 7.14 12.49% -70.12%
Novo Nordisk A Fs 111.24 -0.40 -0.36% 30.79%
Pfizer 52.36 0.72 1.39% 33.27%
Peregrine Pharmaceuticals 16.36 1.03 6.72% -38.29%
Sanofi 98.12 1.00 1.03% 13.04%
Xencor 30.45 1.59 5.51% -11.84%

Indexes Price Day Year
USND 11376 54.19 0.48% -22.43%
US2000 1745 3.34 0.19% -22.56%

MannKind
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.